KR20140098566A - Composition for promoting digestion containing medicinal herb and microorganism - Google Patents

Abstract

The present invention relates to a composition containing medicinal herbs and microorganisms for promoting digestion, a food composition, and a pharmaceutical composition for treating gastrointestinal diseases. The compositions contain medicinal herbs having fewer side effects even for a long period of time of taking and microorganisms having beneficial effects on human body, thereby having a significantly improved digestive effect than digestive effects on carbohydrates, proteins, and the like of a conventional oriental digestive medicine. Further, the compositions also have effects of conventional probiotics such as intestinal regulation, immunity enhancement, anti-inflammation, etc.

Description

TECHNICAL FIELD [0001] The present invention relates to a composition for promoting digestion, comprising a medicinal herb and a microorganism.

The present invention relates to a composition for promoting digestion, a food composition comprising a medicinal herb and a microorganism, and a pharmaceutical composition for treating digestive system diseases.

The herbal digestive system has been used to enhance the gastrointestinal motility or to improve the digestibility of the digestive enzymes such as crusts, pale yellow, lobular lobes, miscarriages, health, broiler, wreaths, It is made by mixing the medicinal materials having the digestive function, the hemostatic function and the analgesic action at an appropriate ratio. The herbal digestive agent is a herbal medicine which restores the digestive function of the human body when taken over a long period of time.

On the other hand, probiotics are collectively called living microorganisms that play a beneficial role in the host. According to the definitions of FAO and WHO by supplying an appropriate amount of the human body, called probiotics alive microorganisms that provide healthy body, the lactic acid bacteria, such as bifidus (bifidobacteria), yeast and Bacillus bacteria (bacillus) is available for the probiotics.

According to recent research, probiotics have been reported to have a wide range of potency, including immunity, anticancer, diarrhea, and anti-inflammation. Specific examples of such efficacy are:

Probiotics are effective against a variety of gastroenteritis, shortening the duration of illness and reducing the frequency of diarrhea (Pail et al., Kor. J. Food Sci. Technol. 34: 73-78, 2002). In particular, antibiotic-associated diarrhea (AAD) caused by imbalance of intestinal microflora in patients receiving long-term antibiotic treatment has been shown to reduce diarrhea and increase immunity when taken with probiotics (D'Souza et al., BMJ 324: 1361, 2002). Experimental results have also shown that probiotics combine with carcinogenic amines produced during meat cooking to prevent the development of cancer and lower the activity of β-glucuronidase, which is known to cause cancer in digestive systems (Reddy et al, In 8th Internation Symposium on Lactic Acid Bacteria and Health. Animal studies have shown that probiotics lower cholesterol levels in the blood and improve the LDL / HDL ratio by degrading bile, which causes cholesterol to be reabsorbed into the blood (Klaver et al., Appl. Environ. Microbiol. 59 : 1120-1124, 1993).

Probiotics are known to enhance immunity by increasing plasma cells that make IgA and by increasing the ratio of T lymphocytes to NK cells (Reid et al., Clin. Microbiol. Rev. 16: 658-672 , 2003). Clinically, it was effective in treating acute diarrhea of children with rotavirus and traveler's diarrhea in adults. Helicobacter It is known that pylori -induced gastritis also increases the efficacy of treatment with probiotics (Hamilton et al., International Journal of Antimicrobial Agents 22: 360-366, 2003).

Recently, probiotics have been widely used as foods such as yogurt, nutritional supplements, and feed additives. Recently, as the effects of constipation improvement, diet effect, and immunity enhancement have been reported, the market size is getting bigger, Molecular biology, and identification of genomes have been actively studied.

A composition for promoting digestion, a food composition, a pharmaceutical composition, and the like, which contain herbal medicines and microorganisms, in order to exhibit the digestive effect of the herbicide extinguishing agent while showing the efficacy of the probiotics.

However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.

The present invention relates to a composition for promoting digestion, a food composition, and a pharmaceutical composition.

One embodiment of the present invention provides a composition for promoting digestion comprising a medicinal herb and a microorganism, and more particularly, to a composition for promoting digestion which comprises a herb medicine, licorice, health, malt (herb), white papule, , Cloves, petals, and dermis; And at least one microorganism selected from the group consisting of genus Bacillus, genus Lactobacillus, genus Lactococcus, genus Enterococcus, genus Streptococcus and genus Bifidobacterium .

Another embodiment of the present invention provides a composition for promoting digestion comprising a medicinal herb and a microorganism, and more particularly, to a composition for promoting digestion which comprises a herb medicine, licorice, health, malt (herb), white pear, Herbal medicine, clove, clove, petals, and dermis; And at least one microorganism selected from the group consisting of genus Bacillus, genus Lactobacillus, genus Lactococcus, genus Enterococcus, genus Streptococcus and genus Bifidobacterium .

Another embodiment of the present invention provides a composition for promoting digestion comprising a medicinal herb and a microorganism, and more particularly, to a composition for promoting digestion which comprises a herb medicine, licorice, health, malt (herb), white pear, , Herbal extracts, cloves, petals, and dermis; And a microorganism selected from the group consisting of genus Bacillus, genus Lactobacillus, genus Lactococcus, genus Enterococcus, genus Streptococcus and genus Bifidobacterium .

The inventors of the present invention conducted a survey of Bacillus , a kind of probiotics, to identify and isolate and identify probiotics and provide compositions using the same.

Hereinafter, the present invention will be described in detail.

The present invention relates to a composition comprising a medicinal herb and a microorganism. The composition includes herbal medicines having less side effects even when taken over a long period of time, and microorganisms having a beneficial effect on the human body. Thus, the composition has remarkably improved digestive effect than the limited herbal medicines or microorganisms.

One embodiment provides a composition for accelerating digestion comprising herbal medicines and microorganisms. Specifically, the composition is at least one selected from the group consisting of broiler chickens, licorice, health, malt (chopped), white papper, chopped, sour (chopped), acidic chopped, new chopped, excess chopped, cloves, cloves, and dermis; And a microorganism selected from the group consisting of Bacillus genus, Lactobacillus genus, Lactococcus genus, Enterococcus genus, Streptococcus genus, and Bifidobacterium genus.

The composition containing the medicinal herb and microorganism according to the present invention may be a solution in which the medicinal herb is dissolved in a powder or a solvent, a powder of the medicinal herb extract, or a solvent extract of the medicinal herb. The solvent for preparing the solvent extract of the medicinal herb may be, for example, water, ethanol or an aqueous solution of ethanol. In addition, the microorganism is preferably a probitics, that is, a live bacterial preparation, and may be in the form of a microorganism culture or a microorganism. A specific example of the present invention may be a mixed solution obtained by adding dry powder of a medicinal herb to a microorganism culture solution.

The content of the medicinal herb and the microorganism can be appropriately controlled to exhibit an enhanced digestive effect. The composition may have a mixing ratio of herbal medicines and microorganisms of 90:10 to 99.9: 0.01 on a dry weight basis.

Herbal medicines contained in the composition of the present invention are preferably those known as digestive action, eosinophilia, and analgesic effect. The above medicinal herbs release loose glands and enhance the function of the spleen. It is good for the abdominal cavity, trunk, vomiting and so on. It is good for diarrhea. It is good for diarrhea. (Malt), which is effective for licorice, soothing, analgesic, and paracetamol that makes harmful effect appear, and which has a digestive and hypoglycemic action, and a fragrance which is effective for analgesic.

The medicinal herbs are relatively effective medicinal herbs as the main medicinal herbs. Specific examples of medicinal herbs are broilers, licorice, health, malt (chow), Baekduguk, Petals, and dermis may be selected. In addition, the medicinal herb may further include one or more kinds of auxiliary medicinal herbs selected from the group consisting of Baekbok-ri, Munhwa, Munhwa, Sandalwood and Mint.

Preferably, the medicinal herb may be selected from the group consisting of broccoli, licorice, health, malt (herb), white paprika, red pepper, sine (safflower) As the kinds of the auxiliary medicinal materials to be additionally added, at least one kind selected from the group consisting of Baekbok-ryeong, cerebrospinal fluid, uterus, sandalwood, and peppermint can be included.

The content of the main medicinal herb may be, for example, from 50 to 99.9% by weight, preferably from 85 to 99% by weight, based on the weight of the whole composition containing the medicinal herb and microorganism. The additional herbal medicine added may be included in an amount of 1 to 15 parts by weight based on 100 parts by weight of the total composition containing the herbal medicine and the microorganism.

In a specific example of the present invention, the main herb medicine comprises 6 to 9% by weight, 6 to 9% by weight of malt, 12 to 14% by weight of licorice, 12 to 12% by weight of malt 14 to 14% by weight, 6 to 9% by weight, 4 to 7% by weight, 4 to 6% by weight of safflower, 11 to 15% by weight of acidic crab, 4 to 7% by weight and 4 to 6% 7 to 9% by weight, cinnabar 7 to 9% by weight, 4 to 6% by weight of peel, and 7 to 10% by weight of dermis.

Microorganisms contained in the present composition may comprise a means for microbes to a beneficial role in the host, and lactic acid bacteria, known as micro-organisms a beneficial role, for example, such as bifidobacteria (bifidobacteria), yeast, Bacillus bacteria (bacillus).

Specific examples of the microorganisms may be selected from the group consisting of Bacillus genus, Lactobacillus genus, Lactococcus genus, Enterococcus genus, Streptococcus genus, and Bifidobacterium genus, which are known as the action of the digestive system, (4): < RTI ID = 0.0 >

(1) a method of producing a glycerol, a glycerol, a ribose, a glucose, a fructose, N-acetylglucosamine, cellobiose, maltose, saccharose, trehalose ), Starch, turanose, fucose and gluconate; the ability to degrade the carbohydrate selected from the group consisting of starch, starch, turanose, fucose and gluconate;

(2) a fatty acid resolution or protein resolution of from 6 to 12 carbon atoms;

(3) esterase of fatty acids having 8 carbon atoms, leucine acrylamidase, chymotrypsin, acid phosphatase or naphthol-acid phosphatase, AS-BI-phosphohydrolase); And

(4) Resistance to gastric juice and bile acid.

More preferably, the microorganism is selected from the group consisting of Bacillus megaterium , and specifically may be the accession number KACC91778P. The microorganisms were deposited under the accession number KACC91778P deposited at the National Institute of Agricultural Science and Technology, National Institute of Agricultural Science and Technology, 88-20, Seodaun-dong, Kwon Seon-Gu, Suwon-si, Gyeonggi-do.

The content of the microorganism may be, for example, 10 to 20% by weight, based on the weight of the whole composition containing the herb medicine and the microorganism.

The microorganism is a living microorganism, that is, it acts as a probiotics (live bacteria), so that it exerts an effect of promoting the digestion effect and the dressing action. Therefore, the microorganism preferably has a viable cell count of 10 ³ to 10 ¹⁰ CFU / g. For example, 50% by weight or more based on the total weight of the total microorganisms to be added may be viable bacteria.

The present invention relates to a composition comprising a medicinal herb and a microorganism, and can be used as a food composition by an improved digestion effect and a dressing action.

Accordingly, another embodiment provides a food composition containing herbal medicines and microorganisms. The above medicinal materials, microorganisms and contents are as described above.

The food composition may include a food-acceptable food-aid additive.

Examples of the pharmaceutically acceptable food-aid additive include natural carbohydrates, flavors, nutrients, vitamins, minerals (electrolytes), flavors (synthetic flavors, natural flavors and the like), colorants, fillers, At least one component selected from the group consisting of alginic acid and its salt, organic acid, protective colloid thickener, pH adjusting agent, stabilizer, preservative, antioxidant, glycerin, alcohol, carbonating agent and flesh can be used.

Examples of the natural carbohydrate include monosaccharides such as glucose and fructose; Disaccharides such as maltose, sucrose; Polysaccharides such as dextrin, cyclodextrin; And sugar alcohols such as xylitol, sorbitol, and erythritol. Examples of the flavoring agents include natural flavoring agents such as tau Martin and stevia extract (for example, rebaudioside A and glycyrrhizin); And synthetic flavors such as saccharin and aspartame.

The food composition may be prepared in various forms according to conventional methods known in the art. For example, the food composition may be prepared as tablets, capsules, pills, or solutions.

The present invention can also be used as a pharmaceutical composition for the treatment of digestive system diseases due to an improved digestion effect and an action of dressing, including a medicinal herb and a microorganism.

Accordingly, another embodiment provides a pharmaceutical composition for treating digestive system diseases containing herbal medicines and microorganisms. The herbal medicines and microorganisms are as described above.

The gastrointestinal system disease refers to a disease of the organs responsible for digestion and absorption of food, and specifically refers to a dysfunctional or inflammatory disease of the gastrointestinal tract. For example, dyspepsia, stomach pain, gastritis, constipation, diarrhea or irritable bowel syndrome.

The therapeutic pharmaceutical composition may comprise conventional therapeutically active ingredients, other adjuvants, and pharmaceutically acceptable carriers. Examples of suitable carriers, excipients and diluents that may be included in such a composition include pharmaceutically acceptable carriers such as lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, Calcium phosphate, calcium silicate, cellulose, methylcellulose, amorphous cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. The composition may further include, but is not limited to, conventional fillers, extenders, binders, disintegrants, surfactants, anticoagulants, lubricants, wetting agents, perfumes, emulsifiers, preservatives and the like.

In addition, the pharmaceutical composition for therapeutic use may be used in the form of a general pharmaceutical preparation, and when formulated, a pharmaceutically acceptable diluent or excipient may be used. The composition of the present invention may be formulated into various forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, ≪ / RTI > pathway.

Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin, Mix and formulate. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.

Examples of the oral liquid preparation include suspensions, solutions, emulsions, and syrups. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used.

The composition is administered in a pharmaceutically effective amount.

In the present invention, the term pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will depend on the type of disease, severity, activity of the drug, The time of administration, the route of administration and the rate of excretion, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts. For example, in an amount of 0.001 to 100 mg / kg (body weight) per day, preferably 0.01 to 30 mg / kg (body weight) per day, and the dose may be divided into oral ≪ / RTI > pathway.

The composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.

In addition, the dose of the composition may be varied depending on the degree of absorption, body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, severity of disease, The administration can be carried out once a day or divided into several doses.

The composition for promoting digestion, the food composition and the pharmaceutical composition according to the present invention can be used for the production of pharmaceutical compositions such as broiler, licorice, health, malt (herb), white paprika, A step of finely pulverizing the medicinal herb selected from the group consisting of at least one herbicide; The method may further comprise mixing microorganisms selected from the group consisting of Bacillus genus, Lactobacillus genus, Lactococcus genus, Enterococcus genus, Streptococcus genus, and Bifidobacterium genus. In addition, for the convenience of ingestion, the step of mixing may be further followed by a step of molding into a ring shape using a ventilator.

The composition of the present invention includes a herbal medicine having less side effects even when taken over a long period of time and a microorganism having a beneficial effect on the human body, thereby exhibiting a digestive effect remarkably improved than the digestive effects of carbohydrates and proteins shown in conventional herbal digestive agents. In addition, as an application of probiotics, it contains viable microorganisms, and it has the effect of conventional probiotics such as a formal action, a strengthening of immunity, and an anti-inflammatory action.

Therefore, it is expected to be widely applied in related medicine or health functional foods industry as another application of probiotics.

1 shows a flow diagram based on the 16S rDNA nucleotide sequence (SEQ ID NO: 1) of the strain isolated according to Example 1.1.
Figure 2 is a graphical representation of the viable cell count (CFU / ml) of B. megaterium KS12 in artificial gastric juice according to Example 1.3 from 0 to 3 incubation times.
Figure 3 is a graph showing the effect of B. megaterium < RTI ID = 0.0 > The number of live cells (CFU / ml) of KS12 is shown in the graph.
FIG. 4 is a photograph of a clear zone formed according to Example 3.1. FIG.
FIG. 5 is a photograph of a clear zone formed according to Example 3.2 with naked eyes. FIG.
6 is a graphical representation of viable cell counts (CFU / g) in the composition according to Example 3.3.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, these are only for illustrating the present invention, and the scope of the present invention is not limited by these examples.

 [Example]

Example  1. Preparation and activity test of microorganisms

1.1 Isolation and identification of microorganisms

The microbial isolates were cultured on Nutrient Broth (NB) plate medium or liquid medium, and the microorganisms were isolated using anchovy salted fish (Origin: Chungcheongbuk - gun) as a sample. Specifically, the sample was diluted with 0.85% physiological saline and then spread on NB plate medium and cultured at 37 ° C for 2 days. First, microorganisms were isolated using a random selection method, and microorganisms forming endospore were selected.

The morphological and biochemical characteristics and the 16S rRNA gene sequence were examined to identify the isolated microorganisms.

Morphological characteristics were examined by microscopic observation after Gram stain.

Specifically, microbial isolates were isolated, purified by dilution plate method, stained with crystal violet, and treated with 3% iodine / potassium iodine. After washing with alcohol, the cells were counterstained with sapranin And observed with an optical microscope. Observation of purified microorganisms are Gram-positive was identified as Klebsiella (bacillus).

Biochemical characteristics were investigated using API50CHL kit (BioMerieux), and it was confirmed that it corresponds to genus Bacillus .

16S rRNA gene sequencing was performed by using genomic DNA extraction kit (Qiagen) to extract the genomic DNA of the isolated microorganism and then using a universal primer (27F / 1492R) for 16S rDNA amplification. Specifically, 27F (5'-AGA GTT TGA TCM TGG CTC AG-3 ', SEQ ID NO: 2), a primer recognizing a common sequence of bacterial 16S rDNA belonging to the Eubacteria domain, and 1492R (5'-GGY (SEQ ID NO: 3), and the reaction was carried out at 94 ° C for 8 minutes, 48 ° C for 1 minute, and 72 ° C for 2 minutes for 40 cycles, and at 70 ° C for 10 minutes . The amplified PCR product was purified, and the base sequence was analyzed by Solgent Corporation.

Analyzing the nucleotide sequence (SEQ ID NO: 1) was compared with the nucleotide sequence similarity of the eubacteria (Bacillus megaterium) listed in the NCBI database, the result Bacillus 1431 bp of 1432 bp of the 16S ribosomal RNA sequence of megaterium were identical and 99% similarity was observed . Based on this, the isolated bacteria were identified as B. megaterium Lt; / RTI >

1.2 Investigation of physiological characteristics of microorganisms

1) Carbohydrate resolution : The B. megaterium The various carbohydrate resolutions of KS12 were investigated through API50CHL kit, and the results are shown in Table 1 below.

Table 1 shows that B. megaterium The results of various carbohydrate resolutions of KS12 show that '+' indicates resolution, '-' indicates no resolution, and '+/-' indicates less resolution.

Carbohydrate result Carbohydrate result Glycerol + Salicin +/- Erythritol - D-cellobiose + D-arabinose - D-maltose + L-arabinose - D-lactose +/- D-ribose + D-melibiose - D-xylose - D-saccharose + L-xylose - D-trehalose + D-adonitol - Inulin - Methyl-beta -D-xylopyranoside - D-melezitose - D-galactose - D-raffinose - D-glucose + Starch + D-fructose + Glycogen - D-mannose - Xylitol - L-sorbose - Gentibiose - L-rhamnose - D-turanose + Dulcitol - D-lyxose - Inositol - D-tagatose - D-mannitol - D-fucose - D-sorbitol - L-fucose + Methyl-alpha -D-mannopyranoside - D-arabitol - Methyl-α-D-glucopyranoside - L-arabitol - N-acetylglucosamine + Gluconate + Amygdalin - 2-Ketogluconate +/- Arbutin + 5-Ketogluconate + Esculin +

As shown in Table 1, B. megaterium KS12 has excellent resolution for glycerol and monosaccharides such as glucose and fructose, disibodies cellobiose, maltose, saccharose and trehalose. Respectively.

2) Enzyme activity : B. megaterium Activity of various enzymes of KS12 was investigated using API ZYM kit. Specifically, the B. megaterium KS12 isolated and identified by the procedure of 1.1 was cultured in MRS solid medium at 37 ° C for 16 hours, and the cells were recovered and suspended in 0.085% NaCl solution. After that, 65 μl of the suspension was dispensed into the API ZYM kit, and the enzyme activity was examined by observing the color change after culturing at 37 ° C for 4 hours. The results are shown in Table 2 below.

Table 2 shows that B. megaterium The results of various enzymatic activities of KS12 show that '+' indicates resolution, '-' indicates no resolution, and '+/-' indicates a minimal resolution.

enzyme result Alkaline phosphatase - Estrease (C4) - Esterase (C8) + Lipase (C14) - Leucine acrylamidase + Valine acrylamidase +/- Crystine acrylamidase - Trypsin - α-Chymotrypsin + Acid phosphatase + Naphtol-AS-BI-phosphohydrolase + α-Galactosidase - β-Galactosidase - β-Glucuronidase - α-Glucosidase - β-Glucosidase - N-Acetyl-β-glucosaminidase - α-Mannosidase - α-Fucosidase -

As shown in Table 2, B. megaterium KS12 had an esterase activity to decompose fatty acids having 8 carbon atoms and α-chymotrypsin, a protease. Other activities of leucine acrylamidase, acid phosphatase and phosphohydrolase were also shown.

1.3 Immunity test of microorganism against artificial gastric juice

Microorganisms must survive in the digestive tract to perform digestion and dressing, and the ingested microorganism must have resistance to stomach juices and bile secreted from the duodenum in order to reach the intestines. In order to confirm whether B. megaterium KS12 isolated by the procedure of 1.1 was resistant to strong acid stomach fluid, the microorganism resistance test was carried out using artificial gastric juice.

Artificial gastric juice was prepared by adding 1,000 uni / ml of pepsin to the MRS liquid medium adjusted to pH 3.0 using 1N HCl according to the method described by Kobayashi et al (J. Microbiol, 29: 691-698, 1974). The isolated B. megaterium KS12 was cultured in MRS medium, centrifuged to recover the cells, and 50 ml of the prepared artificial gastric juice was added and cultured at 30 ° C for 3 hours in MRS medium. The viable cell count of B. megaterium was measured after the culture, and the result is shown in FIG.

Figure 2 shows the effect of B. megaterium < RTI ID = 0.0 > The number of live cells (CFU / ml) of KS12 is shown in the graph.

As shown in Figure 2, even after 3 hours in the artificial gastric juice, B. megaterium The number of viable cells of KS12 was 0.36 × 10 ⁸ CFU / ml, and it maintained 14.4% of 2.5 × 10 ⁸ CFU / ml as the initial live cell number without killing. Considering that the pH of the pure gastric juice is about 2.0, the actual stomach is pH 2.0 or higher due to the buffering action of the ingested food (Shim et al., Kor. J. Food Sci. Technol. 27: 101-104, 1995) B. megaterium KS12 exhibited high acid resistance and showed the possibility of surviving above and moving to the small intestine.

1.4 Immunity test of microorganism against artificial bile

It is a microorganism that has various functions such as a suicide action, and in order to perform a normal function, it has to survive and reach the intestine with tolerance to bile secreted from the pancreas. The isolated B. megaterium To investigate the tolerance of KS12 to bile, survival rate was investigated by treating oxgall (Difco) at a concentration higher than 0.6 g / L, which is the actual intestinal bile.

The artificial bile was prepared by adding sterilized 1% pancreatin to the MRS liquid medium and then adjusting the pH to 6.8 by addition of 1% concentration of 10% oxgall solution. The cells were recovered by centrifugation of B. megaterium KS12 cultured in the artificial gastric juice medium for 3 hours. Then, 50 ml of the artificial bile was added, and the mixture was incubated at 30 ° C. for 24 hours, and B. megaterium The viable cell count of KS12 was measured, and the results are shown in Fig.

Fig. 3 shows the results of culturing B. megaterium The number of live cells (CFU / ml) of KS12 is shown in the graph.

As shown in Fig. 3, 24 hours after the treatment of artificial bile, the initial B. megaterium About 14% of the viable cell counts of KS12 survived and showed high bile acid tolerance. Survival rates in artificial bile solutions of conventional probiotics such as Pedococcus and Leuconostoc are about 10% (Chung et al., Kor. J. Food Preserv., 10: 406-410, 2003, Lee et al , Kor.J.Appl. Microbiol. Biotechnol. 25: 617-622, 1997), B. megaterium KS12 exhibited both acid resistance and resistance to bile juice, and it was judged to have a function as probiotics.

Example  2. Preparation of the composition

(Broth) 120,000 mg, licorice 180,000 mg, health 102,000 mg, malt (sec) 180,000 mg, white poultry 102,000 mg, baekbokryeong 17,500 mg, white 56,000 mg, The herbal medicines of 17,500 mg, 56,000 mg, 102,000 mg of oriental herbs, 102,000 mg of cloves, 56,000 mg of petals, 56,000 mg of sandalwood, 102,000 mg of dermis and 6,000 mg of herbaceae were finely powdered, mg was mixed with the herbal medicines to make a semi-solid state, and then the composition was prepared by using a ventilator.

Example  3. Comparative experiment of composition efficacy

3.1 Measurement of proteolytic activity

The composition (B) prepared in Example 2 and a conventional herbal digestive agent (A) (purchased from Oriental Medicine (Daejeon)) were dissolved in 10 ml of PBS buffer solution and centrifuged. The supernatant was obtained and 0.5% NaCl, 0.3% peptone , And 0.3% skim milk, respectively. The results were shown in FIG. 4. The results are shown in FIG.

FIG. 4 is a photograph showing a clear zone formation formed 48 hours after the inoculation according to the above method. FIG.

As shown in Fig. 4, it was confirmed that both the composition (B) and the comparative group (A) had a clear zone and the activity of proteolytic enzyme. However, it was confirmed that the size of the formed clear zone formed in the composition (B) was 20% larger than that of the clear zone formed in the comparative group (A), and the protein resolution was better.

3.2 Measurement of carbohydrate degradation activity

The supernatant obtained in the same manner as in Example 3.1 was inoculated into a nutrient agar medium supplemented with 0.5% NaCl, 1.0% peptone, and 0.3% soluble starch, and then cultured. The presence and size of the clear zone The activity of carbohydrase was measured by observation, and the results are shown in Fig.

FIG. 5 is a photograph showing a clear zone formation formed 48 hours after inoculation according to the above method. FIG.

As shown in FIG. 5, it was confirmed that both the composition (B) and the comparative group (A) had a clear zone and had carbohydrase activity. However, it was confirmed that the size of the formed clear zone formed in the composition (B) was about 10% larger than that of the clear zone formed in the comparative group (A), and the carbohydrate resolution was better.

3.3 Viable cell count  Measure

1 g of the composition prepared in Example 2 was dissolved in 10 ml of PBS buffer, centrifuged, and the supernatant was taken and diluted 1/10 After 0.1 ml each, the cells were plated on Nutrient Agar medium and cultured at 37 ° C for 24 hours. The number of viable cells of the microorganisms was counted by counting bacterial populations appearing after culturing, and the results are shown in FIG.

FIG. 6 is a graph showing the number of living cells (CFU / g) in the composition measured by the above method.

As shown in FIG. 6, it was confirmed that 3.1 x 10 ⁷ CFU / g of live cells were present in the composition. This indicates that a large number of viable bacteria are present in the composition, which is very advantageous for the dressing action.

It will be understood by those skilled in the art that the foregoing description of the present invention is for illustrative purposes only and that those of ordinary skill in the art can readily understand that various changes and modifications may be made without departing from the spirit or essential characteristics of the present invention. will be. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive.

National Institute of Agricultural Science KACC91778 20121228

<110> Merede Korea Co., Ltd.          DAEJEON UNIVERSITY Industry-University Cooperation Foundation <120> COMPOSITION FOR PROMOTING DIGESTION CONTAINING MEDICINAL HERB AND          MICROORGANISM <130> DPP20129406KR <160> 3 <170> Kopatentin 2.0 <210> 1 <211> 1486 <212> DNA <213> Artificial Sequence <220> <223> 16S rDNA of B. megaterium KS12 <400> 1 aaggctgggg ggtgctataa tgcagtcgag cgaactgatt agaagcttgc ttctatgacg 60 ttagcggcgg acgggtgagt aacacgtggg caacctgcct gtaagactgg gataacttcg 120 ggaaaccgaa gctaataccg gataggatct tctccttcat gggagatgat tgaaagatgg 180 tttcggctat cacttacaga tgggcccgcg gtgcattagc tagttggtga ggtaacggct 240 caccaaggca acgatgcata gccgacctga gagggtgatc ggccacactg ggactgagac 300 acggcccaga ctcctacggg aggcagcagt agggaatctt ccgcaatgga cgaaagtctg 360 acggagcaac gccgcgtgag tgatgaaggc tttcgggtcg taaaactctg ttgttaggga 420 agaacaagta cgagagtaac tgctcgtacc ttgacggtac ctaaccagaa agccacggct 480 aactacgtgc cagcagccgc ggtaatacgt aggtggcaag cgttatccgg aattattggg 540 cgtaaagcgc gcgcaggcgg tttcttaagt ctgatgtgaa agcccacggc tcaaccgtgg 600 agggtcattg gaaactgggg aacttgagtg cagaagagaa aagcggaatt ccacgtgtag 660 cggtgaaatg cgtagagatg tggaggaaca ccagtggcga aggcggcttt ttggtctgta 720 actgacgctg aggcgcgaaa gcgtggggag caaacaggat tagataccct ggtagtccac 780 gccgtaaacg atgagtgcta agtgttagag ggtttccgcc ctttagtgct gcagctaacg 840 cattaagcac tccgcctggg gagtacggtc gcaagactga aactcaaagg aattgacggg 900 ggcccgcaca agcggtggag catgtggttt aattcgaagc aacgcgaaga accttaccag 960 gtcttgacat cctctgacaa ctctagagat agagcgttcc ccttcggggg acagagtgac 1020 aggtggtgca tggttgtcgt cagctcgtgt cgtgagatgt tgggttaagt cccgcaacga 1080 gcgcaaccct tgatcttagt tgccagcatt tagttgggca ctctaaggtg actgccggtg 1140 acaaaccgga ggaaggtggg gatgacgtca aatcatcatg ccccttatga cctgggctac 1200 acacgtgcta caatggatgg tacaaagggc tgcaagaccg cgaggtcaag ccaatcccat 1260 aaaaccattc tcagttcgga ttgtaggctg caactcgcct acatgaagct ggaatcgcta 1320 gtaatcgcgg atcagcatgc cgcggtgaat acgttcccgg gccttgtaca caccgcccgt 1380 cacaccacga gagtttgtaa cacccgaagt cggtggagta accgtaagga gctagccgcc 1440 taaggtggga cagatgattg ggggaagtcg aacaagagcc tagttc 1486 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> &Lt; 223 > 27F (primer) <400> 2 agagtttgat cmtggctcag 20 <210> 3 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> 1492R (primer) <400> 3 ggytaccttg ttacgactt 19

Claims (11)

A herb medicine selected from the group consisting of broiler, licorice, health, malt (chow), white pear, chrysanthemum, sine (chow), wild ginseng, new song, excess chrysanthemum, clove, clove, and dermis; And
Bacillus genus, Lactobacillus genus, Lactococcus genus, Enterococcus genus, Streptococcus genus, and Bifidobacterium genus. The method according to claim 1,
Wherein the composition has a mixing ratio of herbal medicines and microorganisms of 90:10 to 99.9: 0.01 on a dry weight basis. The method according to claim 1,
Wherein the microorganism has at least one characteristic selected from the group consisting of the following (1) to (4):
(1) a method for producing a glycerol, a glycerol, a ribose, a glucose, a fructose, N-acetylglucosamine, cellobiose, maltose, saccharose, trehalose ), Starch, turanose, fucose and gluconate; the ability to degrade the carbohydrate selected from the group consisting of starch, starch, turanose, fucose and gluconate;
(2) a fatty acid resolution or protein resolution of from 6 to 12 carbon atoms;
(3) esterase of fatty acids having 8 carbon atoms, leucine acrylamidase, chymotrypsin, acid phosphatase or naphthol-acid phosphatase, AS-BI-phosphohydrolase); And
(4) Resistance to gastric juice and bile acid. The method according to claim 1,
Wherein said microorganism is Bacillus megaterium with accession number KACC91778P. The method according to claim 1,
Wherein the composition further comprises at least one auxiliary medicinal herb selected from the group consisting of baechobulryeong, cerebrospinal fluid, uterus, sandalwood, and peppermint. The method according to claim 1,
The medicinal herb contains 6 to 9% by weight of chickens, 11 to 14% by weight of liquorice, 6 to 9% by weight of health, 12 to 14% by weight of malt (s), 6 to 9% 7 to 9% by weight of cloves, 7 to 9% by weight of cloves, 4 to 6% by weight of sesame seeds, 4 to 6% by weight of sesame seeds, 11 to 15% 4 to 6% by weight, and dermis of 7 to 10% by weight. A herb medicine selected from the group consisting of broiler, licorice, health, malt (chow), white pear, chrysanthemum, sine (chow), wild ginseng, new song, excess chrysanthemum, clove, clove, and dermis; And
Bacillus genus, Lactobacillus genus, Lactococcus genus, Enterococcus genus, Streptococcus genus, and Bifidobacterium genus. 8. The method of claim 7,
Wherein the food composition is a tablet, a capsule, a pill or a liquid. A herb medicine selected from the group consisting of broiler, licorice, health, malt (chow), white pear, chrysanthemum, sine (chow), wild ginseng, new song, excess chrysanthemum, clove, clove, and dermis; And
Wherein the microorganism is selected from the group consisting of Bacillus genus, Lactobacillus genus, Lactococcus genus, Enterococcus genus, Streptococcus genus, and Bifidobacterium genus. 10. The method of claim 9,
Wherein said digestive system disease is dyspepsia, gastric, gastritis, constipation, diarrhea or irritable bowel syndrome. 10. The method of claim 9,
Wherein the composition is a powder, granule, tablet, capsule, suspension, emulsion, syrup or aerosol.

Images